中文
English
自由容器-副本2
About Us
RedCloud Bio is an innovative biotech company integrating experimental structural
pharmacology and computing technologies for the advancement of small molecule
drug discovery and development. The Company has laboratories in Shanghai and
Beijing.
RedCloud Bio has accumulated structural data covering targets of
potential clinical value. With this foundation, RedCloud Bio has built its
pipeline targeting tumor resistance as well as rare and other critical diseases
with high unmet medical needs, using its core technology platform.
The Company’s lead therapeutic candidate, H002, is a small molecule
compound addressing EGFR activating mutations. The compound is a
next-generation TKI with unique clinical differentiation for non-small cell
lung cancer and is expected to shortly enter global clinical development.
自由容器-副本2
RedCloud Bio’s structural pharmacology approach has enabled the company
to gain precise understandings of the molecular structure and mechanisms of
action for critical mutations - a crucial for rational design and optimization
of new drug candidates. The Company has integrated state-of-the-art screening
algorithms and molecular dynamics /computational chemistry-based compound
optimization - specific, efficient resources that facilitate discovery of
promising new small molecule drugs.
Contact Us
Nanjing | 307-311, Building No.9, 669-8 Xuanwu Avenue, Xuanwu District
Shanghai | Suite 901, 880 Xiangyang Road, Minhang District
Beijing | Suite 205, Building No.2, PKUCare Industrial Park,
Changping District
Website：https://www.redcloudbio.com
Email：IR@redcloudbio.com
Follow us on WeChat: RedCloudBio
2022 © RedCloudBio Co., Ltd. All Rights Reserved